Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review

Alan L. Myers(The University of Texas Health Science Center), Börje S. Andersson(The University of Texas MD Anderson Cancer Center), Romi Ghose(University of Houston), Jitesh D. Kawedia(The University of Texas MD Anderson Cancer Center), Mark Kramer(Harvard University Press), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Yago Nieto(The University of Texas MD Anderson Cancer Center)
Expert Opinion on Drug Metabolism & Toxicology
August 2, 2017
10.1080/17425255.2017.1360277
Cited by 121

Related Papers

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
|Blood|2001|570
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]
|Blood|1995|539